<DOC>
	<DOCNO>NCT02560740</DOCNO>
	<brief_summary>Chemotherapy-induced peripheral neuropathy ( CIPN ) progressive , endure , often irreversible condition feature pain , numbness , tingle sensitivity cold hand foot ( sometimes progress arm leg ) afflict 30 40 percent patient undergoing chemotherapy . American Society Clinical Oncology ( ASCO ) guidance The Journal Clinical Oncology ( JCO , 2014 April 14 ) recommend prophylaxis regimen CIPN . PerOx Quench unique membrane protection anti-oxidative function special food , 's try explore preventive effect CIPN prevention induce Oxaliplatin colorectal cancer gastric cancer chemotherapy .</brief_summary>
	<brief_title>A Study Efficacy Safety PerOx Quench Prevention Oxaliplatin Treatment Induced Neuropathy</brief_title>
	<detailed_description>This study use two stage group-sequential sampling design , base current data , assume CIPN incidence rate 50 % placebo arm , 20 % PerOx Quench arm（60 % reduction） , set a=0.05，80％ power , random allocation ratio 1:1 , obtain subject number 41（total 82 ) PASS 11 software superior design ; consider 10 % drop rate , final number subject totally 90 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Age 18－80 year old , male female 2 . Without anticancer treatment randomization , ECOG score 02 3 . Estimate bear least 4 cycle chemotherapy treatment normal function heart , lung , liver kidney . 4 . Survival expectation ≥6 month 5 . Signed Informed Consent Form , willing follow study procedure 1 . Received chemotherapy treatment within 4 week randomization . 2 . Current peripheral neuropathy ( chemotherapy , diabetes mellitus , alcoholic disease ) relative symptom relevant treatment . 3 . Concurrent treatment within 30 day randomization follow drug : CalciumMagnesium injection , glutathione , similar ingredient PerOx Quench ( polyene phosphatidyl choline ) . 4 . Laboratory test find suitable chemotherapy patient ( Absolute neutrophil count &lt; 2.0×10*9/L &lt; 2,000/mm3 &gt; ; platelet count &lt; 100× 10*9/L &lt; 100,000/mm3 &gt; ; hemoglobin &lt; 10/dl ; serum total bilirubin &gt; 2 Upper Limit Of Normal ( ULN ) , alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &gt; 3 Upper Limit Of Normal ( ULN ) ; serum creatinine &gt; 1.5 Upper Limit Of Normal ( ULN ) &lt; creatinine clearance rate ≤60ml/min &gt; ） . 5 . Pregnancy , lactation reluctant use contraception woman . 6 . Patients symptomatic brain metastasis mental disorder could self assessment . 7 . Alcohol and/or drug abuse doctor determine compliance 's claim . 8 . Within month clinical trial subject . 9 . Once group study , random within eight week use product . 10. personnel involve study . 11 . Not complete independent self assessment patient . 12 . Other researcher determine fit participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>